[go: up one dir, main page]

Konturek et al., 1980 - Google Patents

Effect of ranitidine, a new H2-antagonist, on gastric and pancreatic secretion in duodenal ulcer patients

Konturek et al., 1980

Document ID
7191142894668363542
Author
Konturek S
Obtulowicz W
Kwiecień N
Sito E
Oleksy J
Miszczuk-Jamska B
Publication year
Publication venue
Digestive Diseases and Sciences

External Links

Snippet

The effects of a new H2-receptor blocker, ranitidine, given intravenously (for comparison with cimetidine) or orally on gastric and pancreatic secretion have been studied in duodenal ulcer patients. Ranitidine appears to be several times more potent and a longer-acting …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds

Similar Documents

Publication Publication Date Title
EP0995440B1 (en) Method to increase the blood, glucose level in mammals
Seyer-Hansen Postprandial hypotension
RU2189233C2 (en) Use of effectors decreasing activity of dipeptidyl-peptidase (dp iv) and enzyme dp iv respectively with similar activity for decrease of blood glucose level
Mason et al. Cyclosporine 1 and the renin-angiotensin system.
Konturek et al. Effect of ranitidine, a new H2-antagonist, on gastric and pancreatic secretion in duodenal ulcer patients
AU755949B2 (en) A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
Smith et al. Famotidine, a new H2-receptor antagonist: effect on parietal, nonparietal, and pepsin secretion in man
EP0699440B1 (en) Use of a ascorbyl tocopheryl phosphate for the manufacture of a medicament for the treatment of pancreatitis
EP0708644A1 (en) TREATMENT OF $i(CRYPTOCOCCUS NEOFORMANS) INFECTION
Jansen et al. Somatostatin analog octreotide (SMS 201–995) prevents the decrease in blood pressure after oral glucose loading in the elderly
Ajayi et al. Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.
Drayer et al. The possible importance of aldosterone as well as renin in the long-term antihypertensive action of propranolol
Stöckmann et al. Long-term treatment of patients with endocrine gastrointestinal tumours with the somatostatin analogue SMS 201-995
Cagnoli et al. Relation between hydrocarbon exposure and the nephrotic syndrome
Semple et al. Onset of action of captopril, enalapril, enalaprilic acid and lisinopril in normal man
US4443434A (en) Antiulcer agent
Leslie et al. Absence of blood-pressure lowering effect of captopril in anephric patients.
Moreau et al. Comparison of Somatuline (BIM‐23014) and somatostatin on endocrine and exocrine activities in the rat
Bursztyn et al. Effects of a novel renin inhibitor in patients with essential hypertension
Madsen et al. The influence of captopril on the epinephrine response to insulin-induced hypoglycemia in humans: the interaction between the renin-angiotensin system and the sympathetic nervous system
Konturek et al. Effect of orally administered 15 (R)-15-methyl prostaglandin E2 and/or an anticholinergic drug on meal-induced gastric acid secretion and serum gastrin level in patients with duodenal ulcers
Bing et al. Indapamide and bendrofluazide: a comparison in the management of essential hypertension.
Behrmann et al. Blood histamine levels in experimental burns
Opocher et al. Effect of verapamil on aldosterone secretion in primary aldosteronism
Konturek et al. Dynamics of gastric acid inhibition by ranitidine in duodenal ulcer patients